Skip to main content

Advertisement

SpringerLink
Log in

APL, a model disease for cancer therapies?

  • Review
  • Published:
Oncogene Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

PML:

promyelocytic leukemia

APL:

acute promyelocytic leukemia

NBs:

nuclear bodies

ATRA:

all trans retinoic acid

As2O3:

arsenic trioxide

PLZF:

promyelocytic zinc finger

RAR:

retinoic acid receptor

IFN:

interferon

SUMO:

small ubiquitin modifier

References

  • Benoit G, Altucci L, Flexor M, Ruchaud S, Lillehaug J, Raffelsberger W, Gronemeyer H, Lanotte M . 1999 EMBO J. 18: 7011–7018

  • Brasch K, Ochs RL . 1992 Exp. Cell. Res. 202: 211–223

  • de Thé G, Rivière M, Bernhard W . 1960 Bull. Cancer. 47: 570–584

  • de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A . 1991 Cell 66: 675–684

  • Fagioli M, Alcalay M, Pandolfi PP, Venturini L, Mencarelli A, Simeone A, Acampora D, Grignani F, Pelicci PG . 1992 Oncogene 7: 1083–1091

  • Gianni M, Koken MHM, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z, de The H . 1998 Blood 91: 4300–4310

  • Gottifredi V, Prives C . 2001 Trends Cell Biol. 11: 184–187

  • Grignani F, de Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seister C, Grignani F, Lazar MA, Minucci S, Pelicci PG . 1998 Nature 391: 815–818

  • He L, Bhaumik M, Tribioli C, Rego EM, Ivins S, Zelent A, Pandolfi PP . 2000 Mol. Cell 6: 1131–1141

  • Huang M, Ye Y, Chen R, Chai J, Lu J, Zhoa L, Gu L, Wang Z . 1988 Blood 72: 567–572

  • Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T, Yeh E, Strauss J, Maul G . 1999 J. Cell Biol. 147: 221–234

  • Koken MHM, Linares-Cruz G, Quignon F, Viron A, Chelbi-Alix MK, Sobczak-Thépot J, Juhlin L, Degos L, Calvo F, de Thé H . 1995 Oncogene 10: 1315–1324

  • Lallemand-Breitenbach V, Guillemin M-C, Janin A, Daniel M-T, Degos L, Kogan SC, Bishop JM, de The H . 1999 J. Exp. Med. 189: 1043–1052

  • Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R . 1991 Blood 77: 1080–1086

  • Lin RJ, Nagy L, Inoue S, Shao WL, Miller WH, Evans RM . 1998 Nature 391: 811–814

  • Melnick A, Licht JC . 1999 Blood 93: 3167–3215

  • Michaelson JS, Bader D, Kuo F, Kozak C, Leder P . 1999 Genes Dev. 13: 1918–1923

  • Muller S, Hoege C, Pyrowolakis G, Jentsch S . 2001 Nat. Rev. Mol. Cell. Biol. 2: 202–210

  • Pelicano L, Brumpt C, Pitha PM, Chelbi-Alix MK . 1999 Oncogene 18: 3944–3953

  • Pollock JL, Westervelt P, Kurichety AK, Pelicci PG, Grisolano JL, Ley TJ . 1999 Proc. Natl. Acad. Sci. USA 96: 15103–15108

  • Quignon F, Chen Z, de Thé H . 1997 Biochim. Biophys. Acta 1333: M53–M61

  • Regad T, Saib A, Lallemand-Breitenbach V, Pandolfi PP, de Thé H, Chelbi-Alix M . 2001 EMBO J. 20: 3493–3505

  • Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WHJ . 1998 J. Natl. Cancer Inst. 90: 124–133

  • Terris B, Baldin V, Dubois S, Degott C, Flejou JF, Henin D, Dejean A . 1995 Cancer Res. 55: 1590–1597

  • Vahdat L, Maslak P, Miller Jr WH, Eardley A, Heller G, Scheinberg DA, Warrell Jr RP . 1994 Blood 84: 3843–3849

  • Zhong S, Salomoni P, Ronchetti S, Guo A, Ruggero D, Pandolfi PP . 2000 J. Exp. Med. 191: 631–639

Download references

Acknowledgements

We warmly thank all colleagues who agreed to participate in the making of this issue, in particular M Lanotte for the resistant NB4 nomenclature and P Freemont for the PML isoforms nomenclature and all colleagues for consenting to use these nomenclatures.

Author information

Authors and Affiliations

  1. CNRS UPR 9051 Hôpital St. Louis 1, avenue C. Vellefaux, Paris Cedex, 75475, 10, France

    Hugues de Thé

  2. CNRS UPR 9045 Institut André Lwoff 7, rue Guy Moquet, Villejuif Cedex, 94801, France

    Mounira K Chelbi-Alix

Authors
  1. Hugues de Thé
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mounira K Chelbi-Alix
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hugues de Thé or Mounira K Chelbi-Alix.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Thé, H., Chelbi-Alix, M. APL, a model disease for cancer therapies?. Oncogene 20, 7136–7139 (2001). https://doi.org/10.1038/sj.onc.1204851

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204851

  • Springer Nature Limited

Keywords

This article is cited by

Search

Navigation